Fluconazole in the Treatment of Cutaneous Leishmaniasis Caused byLeishmania braziliensis: A Randomized Controlled Trial
Authors:
Open Access
- 1 November 2016
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 64 (1) , 67-71
Abstract
The treatment of cutaneous leishmaniasis (CL) caused by Leishmania braziliensis in Brazil with pentavalent antimony (Sbv) is associated with a high rate of failure, up to 45% of cases. In addition, Sbv can only administered parenterally and has important toxic effect. An effective, safe, and oral treatment for CL is required. A randomized controlled clinical trial was conducted to compare the efficacy and safety of high-dosage oral fluconazole (6.5–8.0 mg/kg/d for 28 days) versus a standard Sbv protocol (20 mg/kg/d for 20 days) for the treatment of CL in Bahia, Brazil. A total of 53 subjects were included in the trial; 26 were treated with Sbv, and 27 with fluconazole. Intention-to-treat analysis showed initial cure rates (2 months after treatment) of 22.2% (6 of 27) in the fluconazole and 53.8% (14 of 26) in the Sbv group (P = .04). Six months after treatment, the final cure rate remained the same in both groups, without any relapses. The frequencies of adverse effects in the Sbv and fluconazole groups were similar, 34.6% versus 37% respectively. One patient treated with fluconazole discontinued treatment owing to malaise, headache, and moderate dizziness (Common Terminology Criteria for Adverse Events grade 2). Oral fluconazole at a dosage of 6.5–8 mg/kg/d for 28 days should not be considered an effective treatment for CL caused by L. braziliensis. NCT01953744.Keywords
Funding Information
- National Council of Scientific and Technological Development (40/2012)
- Research for Neglected Diseases (404129/2012-9)
This publication has 34 references indexed in Scilit:
- Interventions for American Cutaneous and Mucocutaneous Leishmaniasis: A Systematic Review UpdatePLOS ONE, 2013
- Epidemiological and Clinical Changes in American Tegumentary Leishmaniasis in an Area of Leishmania (Viannia) braziliensis Transmission Over a 20-Year PeriodThe American Journal of Tropical Medicine and Hygiene, 2012
- Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil: A Randomized and Controlled TrialPLOS Neglected Tropical Diseases, 2010
- Cutaneous leishmaniasisClinics in Dermatology, 2007
- Drug Resistance in LeishmaniasisClinical Microbiology Reviews, 2006
- Antimony plus Recombinant Human Granulocyte‐Macrophage Colony‐Stimulating Factor Applied Topically in Low Doses Enhances Healing of Cutaneous Leishmaniasis Ulcers: A Randomized, Double‐Blind, Placebo‐Controlled StudyThe Journal of Infectious Diseases, 2004
- Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate.The American Journal of Tropical Medicine and Hygiene, 2001
- Chemotherapy of cutaneous leishmaniasis: a reviewMedical Microbiology and Immunology, 2001
- Cutaneous leishmaniasis. Treatment with itraconazoleArchives of Dermatology, 1989
- Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotesMolecular and Biochemical Parasitology, 1988